Fate Therapeutics Inc (FATE)

[jondoeuk]

Naturally, HLA-G blocks immune cell function by binding the inhibitory receptors ILT2 and ILT4. All active isoforms of HLA-G must engage the D1 and D2 domains of ILT2 and ILT4. So, to overcome this, extracellular domains from ILT2 or ILT4 that bind with HLA-G are fused with intracellular signaling domains that activate NK cell function. NKILT's activation mechanism utilises the disulphide-linked dimerisation of HLA-G to promote CIR dimerisation and NK cell activation.